Procter & Gamble Health Limited (PGHL.BO)
INR 5104.95
(-0.72%)
INR 5104.95
(-0.72%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 3.01 Billion INR | -10.62% |
| 2022 | 3.42 Billion INR | 21.57% |
| 2021 | 2.8 Billion INR | 4.57% |
| 2020 | 2.63 Billion INR | 24.6% |
| 2019 | 2.55 Billion INR | 47.86% |
| 2018 | 1.78 Billion INR | -9.86% |
| 2017 | 1.18 Billion INR | -1.99% |
| 2016 | 1.56 Billion INR | 33.41% |
| 2015 | 1.22 Billion INR | 108.18% |
| 2014 | 595.7 Million INR | -24.87% |
| 2013 | 792.9 Million INR | -25.6% |
| 2012 | 1.06 Billion INR | 28.52% |
| 2011 | 829.2 Million INR | -29.22% |
| 2010 | 1.17 Billion INR | 12.66% |
| 2009 | 1.03 Billion INR | 6.68% |
| 2008 | 974.8 Million INR | -8.44% |
| 2007 | 1.06 Billion INR | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 1.17 Billion INR | 288.61% |
| 2023 FY | - INR | -10.62% |
| 2023 Q4 | 482.5 Million INR | -31.1% |
| 2023 Q3 | 700.3 Million INR | -34.45% |
| 2023 Q2 | 1.06 Billion INR | 12.8% |
| 2023 Q1 | 947.1 Million INR | 86.88% |
| 2022 Q4 | 506.8 Million INR | -38.57% |
| 2022 FY | - INR | 21.57% |
| 2022 Q3 | 825 Million INR | -28.21% |
| 2022 Q2 | 1.14 Billion INR | 21.94% |
| 2022 Q1 | 942.4 Million INR | 37.34% |
| 2021 Q1 | 811.1 Million INR | 59.48% |
| 2021 Q3 | 711.2 Million INR | 6.88% |
| 2021 Q4 | 686.2 Million INR | -3.52% |
| 2021 Q2 | 665.4 Million INR | -17.96% |
| 2021 FY | - INR | 4.57% |
| 2020 Q3 | 339.7 Million INR | -64.04% |
| 2020 Q2 | 944.7 Million INR | 11.38% |
| 2020 FY | - INR | 24.6% |
| 2020 Q1 | 848.2 Million INR | 59.76% |
| 2020 Q4 | 508.6 Million INR | 49.72% |
| 2019 FY | - INR | 47.86% |
| 2019 Q3 | 587.39 Million INR | 0.0% |
| 2019 Q1 | 499 Million INR | -8.5% |
| 2019 Q4 | 530.91 Million INR | -9.62% |
| 2018 Q2 | 153.45 Million INR | -73.63% |
| 2018 FY | - INR | -9.86% |
| 2018 Q4 | 545.38 Million INR | 8.82% |
| 2018 Q3 | 501.19 Million INR | 226.61% |
| 2018 Q1 | 581.96 Million INR | 18.04% |
| 2017 FY | - INR | -1.99% |
| 2017 Q4 | 493.02 Million INR | 186.59% |
| 2017 Q3 | 172.03 Million INR | -20.28% |
| 2017 Q2 | 215.8 Million INR | -41.9% |
| 2017 Q1 | 371.45 Million INR | 146.43% |
| 2016 Q1 | 465.2 Million INR | 36.97% |
| 2016 FY | - INR | 33.41% |
| 2016 Q4 | 150.73 Million INR | -48.55% |
| 2016 Q3 | 292.95 Million INR | -28.12% |
| 2016 Q2 | 407.58 Million INR | -12.39% |
| 2015 Q4 | 339.63 Million INR | 102.47% |
| 2015 Q1 | 254.52 Million INR | -19.31% |
| 2015 Q2 | 318.69 Million INR | 25.21% |
| 2015 Q3 | 167.74 Million INR | -47.36% |
| 2015 FY | - INR | 108.18% |
| 2014 Q1 | 294.24 Million INR | -15.36% |
| 2014 Q4 | 315.42 Million INR | 76.41% |
| 2014 Q3 | 178.8 Million INR | 230.09% |
| 2014 FY | - INR | -24.87% |
| 2014 Q2 | -137.44 Million INR | -146.71% |
| 2013 Q2 | 15.39 Million INR | -94.28% |
| 2013 Q3 | 91.24 Million INR | 492.69% |
| 2013 Q4 | 347.65 Million INR | 281.01% |
| 2013 FY | - INR | -25.6% |
| 2013 Q1 | 269.13 Million INR | -3.5% |
| 2012 Q1 | 412.27 Million INR | 26.43% |
| 2012 Q4 | 278.9 Million INR | 21.54% |
| 2012 Q3 | 229.46 Million INR | -51.16% |
| 2012 FY | - INR | 28.52% |
| 2012 Q2 | 469.81 Million INR | 13.96% |
| 2011 Q3 | 163.42 Million INR | -48.31% |
| 2011 Q1 | 281.91 Million INR | 0.0% |
| 2011 FY | - INR | -29.22% |
| 2011 Q4 | 326.1 Million INR | 99.55% |
| 2011 Q2 | 316.16 Million INR | 12.15% |
| 2010 FY | - INR | 12.66% |
| 2009 FY | - INR | 6.68% |
| 2008 FY | - INR | -8.44% |
| 2007 FY | - INR | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Alembic Pharmaceuticals Limited | 9.61 Billion INR | 68.655% |
| Aurobindo Pharma Limited | 61.78 Billion INR | 95.121% |
| Glenmark Life Sciences Limited | 6.86 Billion INR | 56.077% |
| Granules India Limited | 8.6 Billion INR | 64.964% |
| Indoco Remedies Limited | 2.64 Billion INR | -13.878% |
| Achyut Healthcare Limited | 524 Thousand INR | -575167.176% |
| Ajanta Pharma Limited | 12.56 Billion INR | 76.01% |
| Alkem Laboratories Limited | 24.19 Billion INR | 87.541% |
| Alpa Laboratories Limited | 86.12 Million INR | -3399.948% |
| Brooks Laboratories Limited | 41.72 Million INR | -7123.926% |
| AstraZeneca Pharma India Limited | 2.35 Billion INR | -27.902% |
| Bajaj HealthCare Limited | 444.51 Million INR | -578.131% |
| Bliss GVS Pharma Limited | 1.47 Billion INR | -103.809% |
| Dr. Reddy's Laboratories Limited | 88.27 Billion INR | 96.585% |
| Eris Lifesciences Limited | 6.98 Billion INR | 56.854% |
| FDC Limited | 4.4 Billion INR | 31.517% |
| Glenmark Pharmaceuticals Limited | 11.34 Billion INR | 73.427% |
| Gufic Biosciences Limited | 1.48 Billion INR | -103.609% |
| Ind-Swift Laboratories Limited | 6.86 Billion INR | 56.069% |
| Ipca Laboratories Limited | 13.29 Billion INR | 77.334% |
| Jagsonpal Pharmaceuticals Limited | 323.46 Million INR | -831.924% |
| Krebs Biochemicals & Industries Limited | -82.72 Million INR | 3743.792% |
| Lasa Supergenerics Limited | -65.08 Million INR | 4731.838% |
| Laurus Labs Limited | 8 Billion INR | 62.348% |
| Lupin Limited | 36.96 Billion INR | 91.846% |
| Mankind Pharma Limited | 28.09 Billion INR | 89.271% |
| Medicamen Biotech Limited | 245.66 Million INR | -1127.062% |
| Medico Remedies Limited | 150.37 Million INR | -1904.549% |
| Megasoft Limited | 284.73 Million INR | -958.683% |
| NATCO Pharma Limited | 18.79 Billion INR | 83.962% |
| Piramal Pharma Limited | 13.05 Billion INR | 76.911% |
| RPG Life Sciences Limited | 1.28 Billion INR | -135.224% |
| Sigachi Industries Limited | 883.39 Million INR | -241.228% |
| Sun Pharmaceutical Industries Limited | 138.36 Billion INR | 97.821% |
| Suven Pharmaceuticals Limited | 4.67 Billion INR | 35.551% |
| Syncom Formulations (India) Limited | 430.27 Million INR | -600.574% |
| Unichem Laboratories Limited | 742.35 Million INR | -306.059% |
| Wanbury Limited | 985.49 Million INR | -205.878% |
| Windlas Biotech Limited | 781.72 Million INR | -285.611% |
| ZIM Laboratories Limited | 462.09 Million INR | -552.331% |
| Zydus Lifesciences Limited | 56.22 Billion INR | 94.638% |
| Sun Pharma Advanced Research Company Limited | -3.73 Billion INR | 180.788% |
| Divi's Laboratories Limited | 25.43 Billion INR | 88.146% |
| Hester Biosciences Limited | 539.47 Million INR | -458.771% |
| Amrutanjan Health Care Limited | 682.53 Million INR | -341.646% |
| Bal Pharma Limited | 345.59 Million INR | -772.242% |
| Strides Pharma Science Limited | 3.76 Billion INR | 19.929% |
| Venus Remedies Limited | 711.8 Million INR | -323.489% |
| Aarti Pharmalabs Limited | 3.9 Billion INR | 22.894% |
| Nectar Lifesciences Limited | 1.56 Billion INR | -92.762% |
| Shilpa Medicare Limited | 2.58 Billion INR | -16.477% |
| Aarti Drugs Limited | 3.24 Billion INR | 7.21% |
| IOL Chemicals and Pharmaceuticals Limited | 2.6 Billion INR | -15.645% |
| Suven Life Sciences Limited | -992.78 Million INR | 403.632% |
| Ind-Swift Limited | 1.06 Billion INR | -183.025% |
| Valiant Laboratories Limited | 12.73 Million INR | -23562.768% |
| J. B. Chemicals & Pharmaceuticals Limited | 9.33 Billion INR | 67.708% |
| Solara Active Pharma Sciences Limited | -2.82 Billion INR | 206.822% |
| Themis Medicare Limited | 562.6 Million INR | -435.791% |
| Hikal Limited | 2.69 Billion INR | -11.967% |
| Torrent Pharmaceuticals Limited | 35 Billion INR | 91.39% |
| Sequent Scientific Limited | 549.8 Million INR | -448.272% |
| Novartis India Limited | 1.26 Billion INR | -137.485% |
| Wockhardt Limited | 1.08 Billion INR | -179.111% |
| Jubilant Pharmova Limited | 8 Billion INR | 62.348% |
| Biofil Chemicals and Pharmaceuticals Limited | 13.06 Million INR | -22977.63% |
| Neuland Laboratories Limited | 4.74 Billion INR | 36.515% |
| Morepen Laboratories Limited | 1.72 Billion INR | -74.651% |
| Kilitch Drugs (India) Limited | 287.42 Million INR | -948.761% |
| Mangalam Drugs & Organics Limited | 174.94 Million INR | -1623.046% |